Fluidigm Corporation

310 articles with Fluidigm Corporation

• Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference

  9/2/2021

  Fluidigm Corporation announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event.

• CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2

  8/31/2021

  Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of new data further validating the potential of its mass cytometry technologies, including CyTOF® systems and the Maxpar® Direct™ Immune Profiling Assay™

• Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit

  8/9/2021

  Fluidigm Corporation today announced that company management will participate in the following investor event: UBS Genomics 2.0 and MedTech Innovations Summit Wednesday, August 11, 2021 Laguna Beach, California Panel presentation at 8:00 p.m. ET, 5:00 p.m. PT

• Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million

  8/5/2021

  Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the second quarter ended June 30, 2021.

• Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry

  8/5/2021

  Fluidigm Corporation today announced a collaboration and co-marketing agreement with ImaBiotech for service offerings and product development for Imaging Mass Cytometry™ (IMC™).

• Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision MedicineObjective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development

  8/5/2021

  Fluidigm Corporation today announced a co-marketing agreement with Ultivue, Inc., under which the companies will offer a comprehensive portfolio of solutions for biomarker discovery and drug development.

• Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

  7/8/2021

  Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the market.

• Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of OwnershipA New Platform to Simplify Deep Profiling of the Human Immune System

  5/25/2021

  Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the launch of CyTOF® XT, designed to simplify the design and execution of deep cell profiling studies, standardize sample analysis with reproducible workflows and automation and accelerate novel therapeutic development to improve human health.

• Imaging Mass Cytometry Utilized by Global Consortium Focused on New Precision Medicine Approaches for Treatment of Rheumatoid Arthritis

  5/24/2021

  Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has joined the FLAMIN-GO Project consortium of academic and industry leaders in rheumatology, autoimmune disease research, and drug discovery and development to create an organ-on-a-chip solution toward personalized care and improved outcomes for rheumatoid arthr

• Fluidigm to Present at Upcoming Investor Conferences - May 14, 2021

  5/14/2021

  Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced that the company’s management will participate in several upcoming investor conferences and provide updates on the company’s business strategy and growth plans.

• Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time

  5/10/2021

  Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will host a virtual investor event that will showcase competitive advantages of CyTOF® technology,

• Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period

  5/6/2021

  Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the first quarter ended March 31, 2021.

• Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

  5/6/2021

  Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies

• Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results

  4/8/2021

  Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report first quarter 2021 financial results on Thursday, May 6, 2021, after the close of the market.

• FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay

  3/1/2021

  Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the AZOVA™ COVID-19 Test Collection Kit for use with the Fluidigm® Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the company’s Biomark™ HD platform.

• George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

  2/10/2021

  Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced that George Mason University in Fairfax, Va., is providing saliva-based COVID-19 testing using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD system.

• Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results

  2/10/2021

  Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the fourth quarter and full year ended December 31, 2020.

• NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients with COVID-19

  2/9/2021

  Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® mass cytometry technology and the Maxpar® Direct™ Immune Profiling Assay™ will be used in a longitudinal study of approximately 250 pediatric patients infected with SARS-CoV-2, the virus that causes COVID-19.

• Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

  2/4/2021

  Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in investor meetings at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021.

• Helix Specialty Diagnostics Partners with Genomic LTC DX to Provide COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD PlatformMajor Midwest Labs Targeting 3,000 Tests per Day

  1/26/2021

  Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced that Helix Specialty Diagnostics is partnering with Genomic LTC DX to provide COVID-19 testing using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD system.